camostat mesilate
Showing 1 - 25 of 45
COVID-19 Trial in New Haven (Camostat Mesilate, Placebo)
Completed
- COVID-19
- Camostat Mesilate
- Placebo
-
New Haven, ConnecticutYale University
Mar 22, 2022
Covid19, SARS-CoV Infection, Coronavirus Infection Trial in Baltimore (Camostat Mesilate, Bicalutamide 150 mg)
Terminated
- Covid19
- +2 more
- Camostat Mesilate
- Bicalutamide 150 mg
-
Baltimore, MarylandJohns Hopkins Hospital
Sep 15, 2021
Corona Virus Infection, SARS-CoV-2 Infection, SARS-CoV-2 PCR Test Positive Trial in Germany (biological, drug, other)
Completed
- Corona Virus Infection
- +3 more
- Convalescent plasma
- +3 more
-
Freiburg im Breisgau, Baden-Württemberg, Germany
- +5 more
Feb 9, 2022
COVID, Sars-CoV2 Trial in Lexington (Ivermectin, Camostat Mesilate, Artemesia annua)
Terminated
- COVID
- Sars-CoV2
- Ivermectin
- +3 more
-
Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
Jan 18, 2022
COVID-19 Trial in United States (Camostat Mesilate, Placebo)
Completed
- COVID-19
- Camostat Mesilate
- Placebo
-
Palm Springs, California
- +20 more
Jan 13, 2022
Corona Virus Infection Trial in Denmark, Sweden (Camostat Mesilate, Placebo oral tablet)
Recruiting
- Corona Virus Infection
- Camostat Mesilate
- Placebo oral tablet
-
Hjørring, Region Nord, Denmark
- +10 more
Apr 27, 2021
COVID Trial (Camostat Mesilate, Placebo, Hydroxychloroquine)
Withdrawn
- COVID
- Camostat Mesilate
- +2 more
- (no location specified)
Dec 17, 2020
Severe Acute Respiratory Syndrome Trial in Scottsdale, Tucson, Jacksonville (Camostat Mesilate, Standard of Care)
Recruiting
- Severe Acute Respiratory Syndrome
- Camostat Mesilate
- Standard of Care
-
Scottsdale, Arizona
- +2 more
Jan 7, 2021
Covid19, Diabetes, Hypertension Trial in Mexico City (Camostat Mesilate, Artemisia Annua Leaf)
Terminated
- Covid19
- +3 more
- Camostat Mesilate
- Artemisia Annua Leaf
-
Mexico City, None - Non-US/Canada, MexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Jun 15, 2021
Covid19, SARS-COV-2 Infection Trial (DWJ1248, Placebo)
Terminated
- Covid19
- SARS-COV-2 Infection
- DWJ1248
- Placebo
-
Seoul, Korea, Republic ofSamsung Medical Center
Dec 4, 2022
Covid19 Trial in Gent (Camostat, Placebo)
Recruiting
- Covid19
- Camostat
- Placebo
-
Gent, BelgiumGhent University Hospital, Algemene Inwendige Ziekten
Aug 18, 2021
SARS-CoV-2 Infection (COVID-19) Trial in Japan (FOY-305, Placebo)
Completed
- SARS-CoV-2 Infection (COVID-19)
- FOY-305
- Placebo
-
Tokoname, Aichi, Japan
- +24 more
Jun 11, 2021
Sepsis, Sepsis-induced Coagulopathy, Nafamostat Mesilate Trial (Nafamostat mesilate, 5% glucose)
Not yet recruiting
- Sepsis
- +2 more
- Nafamostat mesilate
- 5% glucose
- (no location specified)
Oct 5, 2023
NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)
Recruiting
- NSCLC
- Furmonertinib 160mg
- Furmonertinib 240mg
-
Shanghai, ChinaShanghai Chest hospital
Jan 16, 2023
Sepsis Trial in Beijing (16mg,KB, Placebos)
Recruiting
- Sepsis
- 16mg,KB
- Placebos
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 18, 2022
Fontan Operation, Protein-Losing Enteropathy, Camostat Mesylate Trial (Camostat mesylate)
Not yet recruiting
- Fontan Operation
- +2 more
- Camostat mesylate
- (no location specified)
Jul 23, 2022
Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma Trial in Worldwide (Eribulin
Completed
- Refractory or Recurrent Solid Tumors
- +3 more
- Eribulin mesilate
- Irinotecan hydrochloride
-
Marseille, Bouches-du-Rhône, France
- +38 more
Jun 20, 2022
Covid19 Trial in France (Camostat Mesylate, Placebo)
Terminated
- Covid19
- Camostat Mesylate
- Placebo
-
Argenteuil, France
- +5 more
Jan 27, 2022
Healthy Volunteers Trial in Berlin (Niclosamide, Placebo)
Completed
- Healthy Volunteers
- Niclosamide
- Placebo
-
Berlin, GermanyCharité Research Organisation GmbH
Nov 26, 2021
Sepsis Syndrome, MODS, AKI Trial in Xi'an
Not yet recruiting
- Sepsis Syndrome
- +5 more
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian JiaotongUniversity
May 18, 2022
NSCLC Trial in Shanghai (Furmonertinib 240mg, Furmonertinib 160mg)
Withdrawn
- NSCLC
- Furmonertinib 240mg
- Furmonertinib 160mg
-
Shanghai, ChinaShanghai Chest hospital
Oct 17, 2021
Healthy Trial in Daejeon (DWJ1248)
Recruiting
- Healthy
-
Daejeon, Korea, Republic ofChungnam National University Hospital
Mar 1, 2021